Scholar Rock Holding (SRRK) Shares Outstanding (Weighted Average) (2017 - 2026)
Scholar Rock Holding's quarterly Shares Outstanding (Weighted Average) came in at $10.6 million in Q1 2026, down 90.56% year-on-year from $111.8 million in Q1 2025, and down 90.8% quarter-over-quarter from $114.7 million in Q4 2025.
Scholar Rock Holding has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $10.6 million in Q1 2026.
- For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 90.56% year-over-year to $10.6 million; the trailing twelve-month figure through Mar 2026 stood at $10.6 million (down 90.56% YoY), and the FY2025 full-year result was $114.7 million, up 14.89% from the prior year.
- Shares Outstanding (Weighted Average) for Q1 2026 stood at $10.6 million, down from $114.7 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $114.7 million in Q4 2025, with the low at $2.2 million in Q1 2022.
- Average Shares Outstanding (Weighted Average) over 5 years is $54.1 million, with a median of $27.7 million recorded in 2022.
- Year-over-year, Shares Outstanding (Weighted Average) surged 3540.13% in 2022 and sank 90.56% in 2026.
- Tracing SRRK's Shares Outstanding (Weighted Average) over 5 years: stood at $59.6 million in 2022, then soared by 39.82% to $83.3 million in 2023, then climbed by 19.79% to $99.8 million in 2024, then climbed by 14.89% to $114.7 million in 2025, then sank by 90.8% to $10.6 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $10.6 million (Q1 2026), $114.7 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 177,333.76 Bn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 185,491.37 Bn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 100.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 55.66 Bn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 254.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 16.04 Bn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 132.89 Mn |
| 10 | Scholar Rock Holding | 500.61 Mn | 20.67 Mn | - | 10.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 10.56 Mn |
| Dec 31, 2025 | 114.70 Mn |
| Sep 30, 2025 | 17.36 Mn |
| Jun 30, 2025 | 112.27 Mn |
| Mar 31, 2025 | 111.84 Mn |
| Dec 31, 2024 | 99.84 Mn |
| Sep 30, 2024 | 97.05 Mn |
| Jun 30, 2024 | 17.01 Mn |
| Mar 31, 2024 | 9.16 Mn |
| Dec 31, 2023 | 83.35 Mn |
| Sep 30, 2023 | 24.37 Mn |
| Jun 30, 2023 | 25.40 Mn |
| Mar 31, 2023 | 27.69 Mn |
| Dec 31, 2022 | 59.61 Mn |
| Sep 30, 2022 | 79.34 Mn |
| Jun 30, 2022 | 27.69 Mn |
| Mar 31, 2022 | 2.18 Mn |
| Dec 31, 2021 | 36.71 Mn |
| Sep 30, 2021 | 2.18 Mn |
| Jun 30, 2021 | 2.18 Mn |
| Mar 31, 2021 | 2.18 Mn |
| Dec 31, 2020 | 30.73 Mn |
| Sep 30, 2020 | 29.67 Mn |
| Jun 30, 2020 | 29.69 Mn |
| Mar 31, 2020 | 29.53 Mn |
| Dec 31, 2019 | 27.54 Mn |
| Sep 30, 2019 | 29.23 Mn |
| Jun 30, 2019 | 25.76 Mn |
| Mar 31, 2019 | 25.59 Mn |
| Dec 31, 2018 | 15.66 Mn |
| Sep 30, 2018 | 24.31 Mn |
| Jun 30, 2018 | 6.72 Mn |
| Mar 31, 2018 | 2.80 Mn |
| Dec 31, 2017 | 1.63 Mn |
| Sep 30, 2017 | 1.60 Mn |
| Jun 30, 2017 | 1.60 Mn |